Functional characteristics of N8, a new recombinant FVIII

Haemophilia

Volumn 16, Issue 6, 2010, Pages 878-887

  Christiansen, M L S ^a,b   Balling, K W ^a   Persson, E ^a   Hilden, I ^a   Bagger Sorensen A ^a   Sorensen B B ^a   Viuff, D ^a   Segel, S ^a   Klausen, N K ^a   Ezban, M ^a   Lethagen, S ^a,b   Steenstrup, T D ^a   Kjalke, Marianne ^a  

^a NOVO NORDISK A S   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Factor VIII; FVIII; FVIII:C; Haemophilia A; Thromboelastography

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; HAEMATE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; N8; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING; CATALYSIS; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG PROTEIN BINDING; HEMOPHILIA A; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; FACTOR VIIIA; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN; VON WILLEBRAND FACTOR;

EID: 78049285783     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02333.x     Document Type: Article

References (23)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
2. Berntorp E. Progress in haemophilic care: ethical issues. Haemophilia 2002; 8: 435-8.
3. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439-48.
4. Thim L, Vandahl B, Karlsson J et al. Purification and characterisation of a new recombinant Factor VIII (N8). Haemophilia 2010; 16: 349-59.
5. Ewenstein BM, Collins P, Tarantino MD et al. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. Semin Hematol 2004; 41: 1-16.
6. Pedersen AH, Nordfang O, Norris F et al. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265: 16786-93.
7. Thim L, Bjoern S, Christensen M et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-93.
8. Gale AJ, Cramer TJ, Rozenshteyn D, Cruz JR. Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V. J Biol Chem 2008; 283: 16355-62.
9. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001; 114: 114-20.
10. Hemker HC, Giesen P, Al Dieri R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
11. Carr ME Jr, Martin EJ, Kuhn JG, Ambrose H, Fern S, Bryant PC. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa. Clin Lab 2004; 50: 529-38.
12. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol 2004; 41: 140-4.
13. Barrowcliffe TW. Factor VIII and factor IX Sub-Committee. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost 1993; 70: 876-7.
14. Lenting PJ, Van Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-60.
15. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
16. Vlot AJ, Koppelman SJ, Van Den Berg MH, Bouma BN, Sixma JJ. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85: 3150-7.
17. Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009; 15: 1187-96.
18. Jankowski MA, Patel H, Rouse JC, Marzilli LA, Weston SB, Sharpe PJ. Defining 'full-length' recombinant factor VIII: a comparative structural analysis. Haemophilia 2007; 13: 30-7.
19. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939-42.
20. Hansen JJ, Bolt G, Kjaergaard K, Kristensen C, Steenstrup TD. Generation of recombinant FVIII purification antibody for manufacturing of N8. J Thromb Haemost 2009; 7: 820-1.
21. Newell JL, Fay PJ. Acidic residues C-terminal to the A2 domain facilitate thrombin-catalyzed activation of factor VIII. Biochemistry 2008; 47: 8786-95.
22. Khrenov AV, Ananyeva NM, Saenko EL. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X. Blood Coagul Fibrinolysis 2006; 17: 379-88.
23. Varfaj F, Neuberg J, Jenkins PV, Wakabayashi H, Fay PJ. Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of Factor VIIIa. Biochem J 2006; 396: 355-62.